Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KNSA with free AI briefings, catalyst countdowns, and dilution alerts.

KNSA · Kiniksa Pharmaceuticals International, plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$576.3M Cash on Hand
CF+ Cash Runway
Follow KNSA by email Get an email when KNSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KNSA, unsubscribe in one click. Privacy

📣 What KNSA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rilonacept
FDA approved Feb 2008 · Arcalyst
Recurrent Pericarditis Phase 3 · NCT03737110 Completed
KPL-387 Pericarditis Phase 2/3 · NCT07010159 Recruiting
Mavrilimumab COVID Phase 2/3 · NCT04447469 Completed
Abiprubart Sjögrens Disease Phase 2 · NCT06531395 Terminated
Vixarelimab Chronic Idiopathic Urticaria Phase 2 · NCT03858634 Completed

Also used in these trials (approved or third-party drugs, not KNSA's own candidates): Prednisone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KNSA holds $576.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KNSA files for a raise →

Get the full KNSA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KNSA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.